

16805 U.S. PTO  
022404

Please type a plus sign (+) inside this box ☐

Attorney Docket **P1216R1C1D6**  
PATENT

22386 U.S. PTO  
10/785221  
022404

**EV 385 661 036 US:** Express Mail Number

**February 24, 2004 :** Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Mail Stop PATENT APPLICATION  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**NON-PROVISIONAL APPLICATION TRANSMITTAL UNDER 37 CFR 1.53(b)**

Transmitted herewith for filing is a non-provisional patent application:

Inventor(s) (or Application "Identifier"):

Avi Ashkenazi, San Mateo, CA  
Sherman Fong, Alameda, CA  
Audrey Goddard, San Francisco, CA  
Austin L. Gurney, Belmont, CA  
Mary A. Napier, Hillsborough, CA  
Daniel Tumas, Orinda, CA  
William I. Wood, Hillsborough, CA

Title: COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES  
CHARACTERIZED BY A-33 RELATED ANTIGENS

**1. Type of Application**

- ☐ This application is for an original, non-provisional application.
- ☐ This is a non-provisional application claiming priority to provisional application no. \_\_, filed \_\_, the entire disclosure of which is hereby incorporated by reference.
- ☒ This is a ☐ continuation-in-part ☐ continuation ☒ divisional application claiming priority to continuation application serial number 09/953,499, filed September 14, 2001, which claims priority to 09/254,465, filed March 5, 1999, which claims priority to provisional serial number 60/066,364 filed November 21, 1997 and PCT International application numbers PCT/US98/24855 filed November 20, 1998 and PCT/US98/19437 filed September 17, 1998, the entire disclosures of which are hereby incorporated by reference.

**2. Papers Enclosed Which Are Required For Filing Date Under 37 CFR 1.53(b)  
(Non-provisional )**

75 pages of specification  
5 pages of claims  
1 page(s) of abstract  
24 sheet(s) of drawings  
☒ formal ☐ informal

**3. Declaration or Oath**

*(for new and CIP applications; also for Cont./Div. where inventor(s) are being added)*  
\_\_\_ An executed declaration of the inventor(s) [] is enclosed [] will follow.

*(for Cont./Div. where inventorship is the same or inventor(s) being deleted)*  
\_X\_ A copy of the executed declaration/oath filed in the prior application is enclosed (37 CFR 1.63(d)).

*(for Cont./Div. where inventor(s) being deleted)*  
\_\_\_ A signed statement is attached deleting inventor(s) named in the prior application (see 37 CFR 1.63(d)(2) and 1.33(b)).

**4. Assignment**

*(for new and CIP applications)*  
\_\_\_ An Assignment of the invention to GENENTECH, INC. [] is enclosed with attached Recordation Form Cover Sheet [] will follow.

*(for cont./div.)*  
\_X\_ The prior application is assigned of record to Genentech, Inc.

**5. Amendments (for continuation and divisional applications)**

\_\_\_ Cancel in this application original claims 1-48 of the prior application before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)

\_X\_ A preliminary amendment is enclosed. (Claims added by this amendment have been properly numbered consecutively beginning with the number next following the highest numbered original claim in the prior application.)

6. **Fee Calculation (37 CFR 1.16)**

The fee has been calculated as follows:

CLAIMS FOR FEE CALCULATION					
Number Filed		Number Extra		Rate	Basic Fee 37 CFR 1.16(a)
					\$770.00
Total Claims	15	-20 =	0	X \$18.00	\$0.00
Independent Claims	6	-3 =	3	X \$86.00	\$258.00
Multiple dependent claim(s), if any				+ \$290.00	\$0.00
Filing Fee Calculation					\$1,028.00

7. **Method of Payment of Fees**

The Commissioner is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$1,028.00. **A duplicate copy of this transmittal is enclosed.**

8. **Authorization to Charge Additional Fees**

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR §1.16 and 1.17, or credit overpayment to Deposit Account No. 07-0630. **A duplicate copy of this sheet is enclosed.**

9. **Additional Papers Enclosed**

- ☐ Information Disclosure Statement (37 CFR §1.98) w/ PTO-1449 and citations  
☐ A new Power of Attorney or authorization of agent.  
☒ Letter and Request To Use Computer-Readable Sequence Listing Under 37 CFR § 1.82(e)  
☐ Other: Application Data Sheet and post card.

10. **Maintenance of Copendency of Prior Application (for continuation and divisional applications)**

*[This item must be completed and the necessary papers filed in the prior application if the period set in the prior application has run]*

- \_\_\_\_\_ A petition, fee and/or response has been filed to extend the term in the pending prior application until  
 \_\_\_\_\_ A copy of the petition for extension of time in the **prior** application is attached.

**11. Correspondence Address:**


X Address all future communications to:

Attn: Elizabeth M. Barnes, Ph.D.

Respectfully submitted,  
GENENTECH, INC.

Date: February 24, 2004

By:

  
Elizabeth M. Barnes, Ph.D.

Reg. No. 35,059

Telephone No. (650) 225-4563

09157

PATENT TRADEMARK OFFICE

150082